AbCellera Biologics' fair value estimate has been raised to US$14.63 from US$10.43 following recent clinical data and a new partnership agreement with Jazz Pharmaceuticals. Truist lifted its price target to US$30 from US$12 after Phase 2 four-week VMS data for ABCL635 exceeded expectations, while JonesResearch increased its target to US$25 from US$13, highlighting high complete response rates and a potential multibillion-dollar market opportunity. Benchmark upgraded the stock to Buy from Hold with an US$11 target after the Jazz deal, which includes US$56 million in upfront payments and an additional US$28 million tied to a third discovery program. The revised fair value incorporates a projected 25% revenue decline, a net profit margin outlook of 14.37%, and a future P/E multiple of about 1,489 times.
Abcellera Biologics Inc
Jazz Pharmaceuticals PLC
Truist Financial Corp